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1. Introduction 
Cyclic AMP (cAMP, cyclic 3’, 5’-adenosine monophosphate) was first identified as a 
signalling molecule in 1958 (Rall & Sutherland, 1958), however it was not until 1962 that the 
enzyme responsible for hydrolysis of cAMP was identified and named phosphodiesterase 
(PDE; Butcher & Sutherland, 1962). Shortly afterwards, cyclic GMP (cGMP, cyclic 3’,  
5’-guanosine monophosphate) was identified as another important second messenger that 
was hydrolyzed by PDE (Ashman et al., 1963). PDEs inactivate cAMP or cGMP by 
hydrolizing the 3’ cyclic phosphate bond of the cyclic nucleotide in question (Bender & 
Beavo 2006). Through molecular cloning and sequencing, it is now known that mammalian 
PDEs are encoded by 21 distinct genes (Bender & Beavo, 2006). These 21 genes encode 
protein isoforms of which variants can exist through the use of multiple transcription start 
sites and alternative mRNA splicing (Bender & Beavo, 2006). The 21 identified isoforms 
have been grouped into 11 families based on similarities in amino acid sequence, structure 
and function.  
1.1 Phosphodiesterase are key regulators of cyclic nucleotide signalling cascades 
cAMP is formed from ATP by adenylyl cyclase (Fig. 1; Rall & Sutherland, 1958). Adenylyl 
cyclase is a membrane-bound enzyme that can be activated by the Gǂ subunit, as well as the 
ǃǄ subunit of the G-protein family, by calcium, and by protein kinase C (Tang & Ziboh, 
1991, Iyengar, 1993). Once formed, cAMP activates protein kinase A. Protein kinase A is a 
tetrameric protein composed of two catalytic subunits and two regulatory subunits (Johnson 
& Jameson, 2000; Johnson et al., 2001). Two cAMP molecules bind to each regulatory 
subunit, which results in the release of the active catalytic subunits. Protein kinase A is 
known to phosphorylate proteins involved in cell signalling, apoptosis, ion channel 
regulation, osmotic homeostasis, and protein trafficking (reviewed by Shabb, 2001). Protein 
kinase A can also enter the nucleus where it is known to phosphorylate cAMP-response 
element binding (CREB) protein (Delghandi et al., 2005). Phosphorylated CREB stimulates 
transcription of genes related to cell signalling and proliferation such as brain-derived 
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neurotrophic factor (Delghandi et al., 2005). In addition to signalling through protein kinase 
A, cAMP can directly alter ion channel conductance (reviewed by Wang et al., 2007). 
PDEs also regulate cGMP signalling cascades. The cGMP pathway is activated by nitric 
oxide, which is produced by nitric oxide synthase (Francis et al. 2010). Nitrous oxide 
activates guanylyl cyclase, which can be membrane-bound or cytosolic. Guanyl cyclase 
converts GTP to cGMP, which can go on to activate protein kinase G (Francis et al., 2010). 
The cGMP pathway, regulates smooth muscle relaxation (Walter, 1984), synaptic plasticity 
(Kleppisch & Feil, 2009), and regulation of platelet aggregation (Walter, 1984).  
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Fig. 1. PDEs regulate the cyclic nucleotide signalling pathways. The cAMP pathways is 
activated by adenylyl cyclase (AC) which converts ATP to cAMP. cAMP binds to the 
regulatory subunits (R) of protein kinase A (PKA), causing the release of the catalytic 
subunits (C). The cGMP pathway functions in a similar manner to the cAMP pathway. 
Guanylyl cyclase (GC) catalyzes the conversion of GTP to cGMP which activates protein 
kinase G (PKG). PDEs eliminate active cAMP and cGMP by hydrolyzing the molecules to 
their inactive AMP and GMP forms. 
1.2 Phosphodiesterase isoforms are grouped into families based on similarities in 
catalytic and regulatory domains 
All mammalian PDE isoforms share a conserved catalytic domain consisting of 
approximately 270 amino acids located in the C-terminal half of the protein (Degerman et 
al., 1997; Fig. 2). The catalytic domain is more similar within an individual PDE family 
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(>80% amino acid identity) than between different PDE families (∼25-40% identity). 
Isoforms within PDE families 1, 2, 3, 4, 10 and 11 have dual specificity for both cAMP and 
cGMP, while PDEs within families 7 and 8 specifically hydrolyze cAMP and PDEs within 
families 5, 6 and 9 specially hydrolyze cGMP. The molecular basis for cAMP, cGMP, or 
cAMP/cGMP selectivity is believed to rely on a “glutamine switch” within the PDE 
catalytic domain which refers to an invariant glutamine that takes an orientation that 
favours binding of either cAMP or cGMP based on the presence of surrounding amino 
acid residues (Zhang et al., 2004).  
 
Fig. 2. Structural differences between the various PDE families. The different structural 
subunits that make up the individual PDE families help to dictate catalytic and regulatory 
specificity, as well as subcellular localization of the various PDEs. 
The N-terminal portions of PDEs are widely divergent and contain functional domains that 
confer many of the regulatory and localization properties specific to the different PDE 
families (Degerman et al., 1997; Fig. 2). Isoforms of PDE families 2, 5, 6, and 7 contain two 
GAF domains (named after the proteins in which these domains are found: cGMP-specific 
phosphodiesterases, adenylyl cyclases and transcriptional activator of formate metabolism). 
Binding of cGMP, or cAMP in the case of PDE10, to the GAF domain stimulates enzymatic 
activity (Bender & Beavo, 2006). Isoforms of the PDE1 family share common dual 
Ca2+/Calmodulin binding sites, which, when bound by Ca2+/Calmodulin, stimulates 
enzymatic activity(Bender & Beavo, 2006). PDE3 isoforms contain hydrophobic domains 
near the N-terminus, which are believed to localize these enzymes to the plasma membrane 
(Degerman et al., 1997). PDE3 isoforms are also unique in that they are inhibited by cGMP, 
though the functional domain responsible for this has not been identified (Degerman et al., 
1997). PDE6 isoforms contain an inhibitory subunit (Ǆ), which must be removed to stimulate 
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catalytic activity (Bender & Beavo, 2006). PDE7 isoforms contain hydrophobic localization 
domains (Bender & Beavo, 2006). PDE8 isoforms contain PAS domains (named after the 
three proteins in which it occurs: period circadian protein, aryl hydrocarbon receptor 
nuclear translocator protein, single-minded protein), and REC, or receiver, domains, which 
are believed to function as environmental sensors (Bender & Beavo, 2006).  Members of PDE 
families 1, 3, 4, 5, and 10 also contain phosphorylation sites which are known to play a role 
in activating or inhibiting enzymatic activity depending on the phosphorylation site in 
question (Bender & Beavo, 2006). 
1.3 Subcellular localization of PDE isoforms plays an important role in 
compartmentation of cyclic nucleotide signalling 
An important idea to come about in the last few years regarding cyclic nucleotide signalling 
is that of compartmentation of cAMP and cGMP (Bender & Beavo, 2006). Unique 
localization and protein-protein interaction domains allow PDEs isoforms to localize to 
specific areas of the cell which allows for compartmentation of cyclic nucleotides (Bender & 
Beavo, 2006). Because adenyl cyclase and some proportion of guanyl cyclase is membrane-
bound, localization of PDEs to the membrane plays an important role in controlling cyclic 
nucleotide signalling. As previously discussed, PDE3A and PDE3B contain hydrophobic 
domains that can localize these proteins to the membrane. Hydrophobic domains are also 
found in PDE2A2, PDE2A3, and PDE4A1 (Bender & Beavo, 2006). Arrestin binding domains 
in PDE4 isoforms are also known to allow PDE4 isoforms to localize to arrestin / ǃ- adrenergic 
receptor complexes where they can breakdown cyclic nucleotides and inhibit ǃ-adrenergic 
receptor signalling (Baillie et al., 2003).  
Subcellular localization of individual isoforms can also change through regulatory 
mechanisms. This is exemplified with PDE10A2 in medium spiny projection neurons (Fig. 
3). When cAMP levels are low PDE10A2 is palmitoylated and becomes associated with 
vesicles or the plasma membrane (Charych et al., 2010). Once at the plasma membrane, 
PDE10A2 is trafficked to dendritic processes throughout the neuron where it may serve to 
regulate intracellular signalling cascades associated with dopaminergic and glutamatergic 
synapses (Charych et al., 2010). When levels of cAMP increase however PKA becomes 
activated which leads to phosphorylation of PDE10A2. Phosphorylation of PDE10A2 
inhibits palmitoylation, which results in the cytosolic accumulation of PDE10A2 in the cell 
body where it can normalize cAMP levels through its catalytic activity (Charych et al., 2010). 
Consequently, subcellular localization of PDEs plays an important role in compartmentation 
of cyclic nucleotide signalling. 
1.4 Conclusions 
PDEs regulate cyclic nucleotide signalling through breakdown of cAMP and cGMP. 
Multiple PDE isoforms are expressed in mammals which differ in catalytic, regulatory and 
subcellular localization properties. Unique regulatory and localization properties allow for 
fine tuning of cyclic nucleotide levels through compartmentation of specific PDE isoforms. 
Properties of isoforms derived from each of the 21 PDE genes encoded in mammals are 
summarized in Table 1. 
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PDE isoforms Preferred substrate Regulatory properties Subcellular localization 
PDE1 
A,B,C 
cAMP/cGMP Ca2+/Calmodulin- 
activated 
Cytosolic 
PDE2 
A 
cAMP/cGMP  GAF+  A1: Cytosolic 
A2, A3: Membrane 
bound 
PDE3 
A,B 
cAMP/cGMP cGMP-inhibited A: Membrane-bound or 
cytoplasmic1  
B: Membrane-
associated  
PDE4 
A,B,C,D 
 
cAMP/cGMP UCR may play as yet 
unknown role 
A,B: Membrane-
associated 
C: Cytosolic 
D: Membrane-bound or 
cytoplasmic1 
PDE5 
A 
cGMP GAF+  Cytosolic 
PDE6 
A,B,C 
cGMP Inhibited by Ǆ 
subunit; GAF+ 
A,B: Membrane 
associated, but becomes 
cytosolic after 
association with ǅ 
subunit  
C: Cytosolic 
PDE7 
A,B 
cAMP Unknown A1:Cytosolic 
A2: Membrane-bound 
PDE8 
A,B 
cAMP PAS and REC 
environmental 
sensors 
Cytosolic 
PDE9 
A 
cGMP No known regulatory 
domains 
A1:Nuclear 
A5: Cytosolic 
PDE10 
A 
cAMP/cGMP GAF+ A1,A3: Cytosolic 
A2: Cytosolic when 
cAMP levels are high, 
membrane associated 
when cAMP levels low  
PDE11 
A 
cAMP/cGMP GAF+ Cytosolic 
1 -Depends on splice variant and cell type. 
Table 1. Properties of PDE isoforms. Adapted from Bender & Beavo (2006), Lugnier (2006), 
and Kleppisch & Feil (2009). Abbreviations: GAF, cGMP-activated PDEs, adenylyl cyclase, 
and transcriptional activator of formate metabolism; UCR, upstream conserved region; PAS, 
period circadian protein, aryl hydrocarbon receptor nuclear translocator protein, single-
minded protein; REC, receiver. 
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Fig. 3. Proposed model for the regulation of PDE10A2 localization in neurons in response to 
fluctuations in cAMP. PDE10A2 protein is synthesized in the cytoplasm. High levels of 
cAMP activate PKA to cause phosphorylation, and thus activation, of PDE10A2. During 
periods of low cAMP, PDE10A2 is palmitoylated and becomes associated with vesicles or 
the plasma membrane. Once at the plasma membrane, PDE10A2 is trafficked to dendritic 
processes throughout the neuron. 
2. Phosphodiesterase isoforms have unique tissue distributions which can 
change during normal physiological processes 
Of the 21 encoded PDE isoforms, only a small sub-set is expressed in any cell type. This cell-
specific expression gives rise to unique distributions of PDE isoforms across tissues. 
Evidence suggests that expression of PDE isoforms changes during normal development 
and aging. Because different isoforms display distinct catalytic, regulatory, and subcellular 
localization properties, tissue-specific expression of PDE isoforms provides a mechanism to 
finely tune cyclic nucleotide levels within an organism.  
2.1 Phosphodiesterase isoforms have unique tissue distributions 
PDE isoforms have unique tissue distributions in the central nervous system (CNS) and non-
nervous tissue. Tissue-specific expression of PDE isoforms was first noted in studies 
examining mRNA and protein expression of individual isoforms using northern blot (Fidock 
et al., 2002; Loughney et al., 1996), in situ hybridization (Prickaerts et al., 2002), western blot 
(Sadhu et al., 1999), and immunohistochemistry (Vandeput et al., 2007). Since then, 
heterogeneous tissue distribution of PDE isoform transcripts has been conclusively shown 
using quantitative reverse transcription (qRT) polymerase chain reaction (PCR) to quantify 
PDE isoform expression profiles in 12 distinct CNS and 12 distinct non-nervous tissues (Lakics 
et al., 2010). The PDE isoforms that are highly expressed in tissues are summarized in Table 2, 
while the relative distribution of highly expressed PDE isoforms across tissues is summarized 
in Table 3. It appears that individual tissues typically express between one and four PDE 
isoforms at high levels (Table 2), and individual PDE isoforms may be expressed at high levels 
in multiple tissues of both the CNS and non-nervous tissues (Table 3). 
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CNS  Non-nervous tissue 
Tissue Highly Expressed PDE Isoforms  Tissue Highly Expressed PDE isoforms 
fCT 2A  THY 8B 
pCT 2A  ADR 2A 
tCT 2A  LIV 2A, 3B, 8A 
HIP 2A  PAN 3A,5A, 8A 
CAU 1B, 10A  STO 5A 
SN 1C, 4B,   INT 2A, 4B, 5A, 9A 
NAC 1B, 2A,   HEA 1C, 3A 
CER 4A, 4B, 9A,10A  MUS 4B, 4D 
THA 1C, 4B,   KID 1A, 4D, 9A 
HPT 1C, 4B  BLA 5A 
DRG 1C, 2A,5A, 9A  LUN 5A 
SPI 4B  SPL 2A 
Table 2. Highly expressed PDE isoforms within a given tissue based on quantitative reverse 
transcription PCR data reported by Lakics et al. (2010). PDE isoforms were considered highly 
expressed if mRNA levels were 60% or higher relative to the most highly expressed isoform 
within a given tissue. fCT, frontal cortex; pCT, parietal cortex; tCT, temporal cortex; HIP, 
hippocampus; CAU, caudate; SN, substantia nigra; NAC, nucleus accumbens; CER, 
cerebellum; THA, thalamus; HPT, hypothalamus; DRG, dorsal root ganglion; SPI, spinal cord; 
THY, thyroid; ADR, adrenal gland; LIV, liver; PAN, pancreas; STO, stomach; INT, intestine; 
HEA, heart; MUS, skeletal muscle; KID, kidney; BLA, bladder; LUN, lung; SPL, spleen. 
Predominant isoform Sites of high expression 
 CNS Non-nervous tissue 
1B CAU  
2A fCT, pCT, tCT, HIP, CAU, NAC SPL 
3A  HEA 
4B fCT, pCT, HIP, CAU, SN, NAC, THA, 
HPT, SPI 
SPL 
5A  BLA, LUN 
7B CAU  
8B  THY 
9A CAU, CER, DRG KID, BLA, SPL 
10A CAU  
11A DRG THY, LIV, PAN, MUS 
Table 3. Sites of high expression for predominant PDE isoforms based on quantitative reverse 
transcription PCR data from Lakics et al. (2010). Expression was considered high if mRNA 
levels were 60% or greater relative to other sites measured. Members of the PDE6 family are 
not shown because PDE6 isoforms are only expressed at appreciable levels in retina, which 
was not tested in this study. fCT, frontal cortex; pCT, parietal cortex; tCT, temporal cortex; 
HIP, hippocampus; CAU, caudate; SN, substantia nigra; NAC, nucleus accumbens; CER, 
cerebellum; THA, thalamus; HPT, hypothalamus; DRG, dorsal root ganglion; SPI, spinal cord; 
THY, thyroid; ADR, adrenal gland; LIV, liver; PAN, pancreas; STO, stomach; INT, intestine; 
HEA, heart; MUS, skeletal muscle; KID, kidney; BLA, bladder; LUN, lung; SPL, spleen. 
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2.2 Expression of phosphodiesterase isoforms can change during development and 
aging 
Expression of PDE isoforms is dynamic and can change during different physiological 
processes such as development and aging. Prickaerts and colleagues (2002) showed that 
PDE5 mRNA is expressed in cerebellar Purkinje cells of rat brains only on and after 
postnatal (P) day 10, whereas PDE9A mRNA is present at 15 days gestation and several 
postnatal stages (P0, P5, P10, P21) until adulthood, thus providing an example of altered 
expression of PDE isoforms during development. Changes to PDE isoform expression 
during aging have also been documented, as PDE5 is significantly decreased in old 
compared to young adult rat brains, while expression of PDE 9 is higher in old compared to 
young rat brains (Prickaerts et al., 2002). Decreases in PDE4 expression have also been 
reported in the in the aging brain, as PDE4A mRNA levels are reduced in striatum of old 
compared to young mice (Hebb et al., 2004). Other PDEs including PDE1B and PDE10A do 
not appear to change with age (Hebb et al., 2004). 
3. Expression of phosphodiesterase isoforms PDE1B, PDE4A, and PDE10A is 
decreased in Huntington’s Disease 
Huntington’s Disease (HD) is caused by the inheritance of a mutant huntingtin gene 
containing an expanded CAG repeat region, which codes for an expanded polyglutamine 
(polyQ) region in the mutant huntingtin (mHtt) protein (reviewed by Zuccato et al., 2010). 
The CAG repeat length of mHtt is inversely correlated with the age of HD symptom 
onset. mHtt is cleaved by caspase enzymes (Graham et al., 2010). The resulting, truncated, 
amino-terminus of mHtt (N-mHtt) translocates to the nucleus. It is thought that the 
nuclear, soluble, N-mHtt interferes with transcription and thus effects gene expression, 
cell function, and survival (Hermel et al., 2004). The neurodegeneration observed during 
HD progression is tissue- and cell-specific, such that the medium spiny neurons of the 
striatum (caudate/putamen) are most severely affected (reviewed by Zuccato et al., 2010). 
Transcriptional dysregulation is a major component of HD pathogenesis. N-mHtt is 
thought to interfere with the assembly of the transcriptional machinery, either through the 
sequestration of certain transcription factors, or through the inappropriate binding and 
interactions with co-factors and transcription factors at the site of transcription initiation. 
Because transcription is dysregulated by N-mHtt during HD pathogenesis, several 
research groups have examined and identified the subset of genes whose expression is 
altered in the presence of N-mHtt to determine how altered gene expression might 
contribute to this disease. The identification of dysregulated genes in HD has been 
completed primarily with mouse models of HD and tissue from human patients suffering 
HD. 
Several transgenic mouse models of HD exist, which can be broadly categorized as models 
over-expressing mHtt or knock-in models expressing mHtt within the mouse huntingtin 
locus at physiologically accurate levels (Heng et al., 2008). Of the over-expression mouse 
models of HD, the mouse N171-82Q, R6, and rat huntingtin cDNA models express N-mHtt 
containing between 82 (N171-82Q) and ~144 (R6/2) CAG repeats and maintain a full 
complement of wild-type, mouse Htt. HD symptom progression and neurodegeneration in 
these models is more rapid than in knock-in models of HD (Heng et al., 2008). Two distinct 
transgenic HD lines are derived from the R6 model: R6/1 and R6/2. R6/1 mice express N-
www.intechopen.com
 
Alterations in Expression and Function of Phosphodiesterases in Huntington’s Disease 141 
mHtt with ~113 CAG repeats and begin to exhibit HD motor symptoms at approximately 13 
weeks of age. R6/2 mice expression N-mHtt with ~144 CAG repeats and begin to exhibit 
HD motor symptoms at approximately 8 weeks of age (Heng et al., 2008). Two other over-
expression models, the mouse YAC128 and the HD cDNA models, express the full-length 
mHtt containing 128 CAG repeats. Disease progression is more rapid in these models than 
in the mouse knock-in models, but less rapid than in rodent models over-expressing N-mHtt 
(Heng et al., 2008). Also, the degree of neurodegeneration, as observed following 
euthanasia, is less severe in the full-length over-expression models than those models over-
expressing N-mHtt (Heng et al., 2008). Knock-in mouse models of HD, including the 
Hdh/Q72 – 80 and Q111 – 150, express exon 1 of the human mutant huntingtin transgene in 
the mouse huntingtin locus. HD motor symptom onset, cognitive decline, and decreased 
socializing behaviours are delayed in these mouse models, relative to other rodent models 
of HD (Heng et al., 2008). Striatal cell loss, gross brain atrophy, and the size and number of 
neuronal intranuclear inclusions are also less prominent in mouse knock-in models of HD. 
Of the transgenic mouse models of HD, the R6 lines have been extensively studied because 
they display many behavioural and physiological changes associated with HD progression 
over a short period of time (Heng et al., 2008). R6/1 mice begin to exhibit motor symptoms 
related to the pathophysiology of HD between 15 and 18 weeks of age. R6/2 mice begin to 
exhibit HD-like symptoms between 8 and 9 weeks of age (Mangiarini et al., 1996). These 
symptoms include increased spontaneous locomotor activity, increased esacape latency in 
the Morris water maze, spatial learning deficits, and progressive rotarod deficit (Cha et al., 
1998). 
3.1 Phosphodiesterase 1B mRNA levels decrease in the striatum of transgenic 
Huntington`s Disease mice prior to symptom onset 
PDE1B mRNA levels are lower in fully symptomatic, 12 week-old, R6/2 HD transgenic mice 
compared to age-matched wild-type mice, as demonstrated by microarray analysis (Luthi-
Carter et al., 2004). Subsequent microarray analyses of PDE1B mRNA expression in 
symptomatic R6/1 mice, N171-82Q HD transgenic mice, a rat model of N-mHtt over-
expression, and cDNA derived from the mRNA of symptomatic HD patients, all provide 
evidence for an N-mHtt-dependent decrease in PDE1B expression (Luthi-Carter et al., 2002; 
Desplats et al., 2006; Crocker et al., 2006; Nguyen et al., 2008). To determine when changes 
were first detected, and how CAG repeat length effected the rate or relative decline, PDE1B 
mRNA expression was measured in the striatum of the R6/1 and R6/2 HD transgenic mice, 
and wild-type mice, using in situ hybridization (Hebb et al., 2004; Fig. 4). An analysis of 
background-corrected optical density for PDE1B mRNA hybridization in coronal sections of 
mouse striatum revealed significant differences between genotypes and across ages. mRNA 
expression of PDE1B was reduced in R6/2 mice, relative to wild-type and R6/1 mice by 4 
weeks of age. A significant decline in PDE1B was detectable by 10 week in R6/1 mice 
compared with wild-type. After the initial decline in transcript level observed in R6/1 and 
R6/2 mice, no further decline occurred. Therefore, PDE1B mRNA expression decreases in 
the presence of N-mHtt in the R6/1 and R6/2 transgenic mouse models of HD prior to 
motor symptom onset (Hebb et al., 2004). Decreased PDE1B expression may be a direct 
effect of expression of N-mHtt, or represent a compensatory mechanism during disease 
progression. 
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Fig. 4. PDE1B expression decreases in the striatum of R6/1 and R6/2 HD transgenic mice 
prior to symptom onset. This figure depicts the optical density of PDE1B mRNA in situ 
hybridization in the lateral striatum of wild-type (WT), R6/1, and R6/2 mice. In both R6/1 
and R6/2 mice, there is an N-mHtt- and age-dependent decrease in PDE1B mRNA. Data 
represents means ± S.E.M. for n = 4 of each genotype and of mice as indicated. * P < 0.01, 
significant difference from age-matched WT. P < 0.01, ~ significant difference from age-
matched R6/1.  
3.2 Phosphodiesterase 10A mRNA and protein levels decrease in the striatum of 
transgenic Huntington`s Disease mice prior to symptom onset 
PDE10A mRNA is expressed in the striatum, nucleus acumbens, and olfactory tubercle of R6 
and wild-type mice. PDE10A mRNA distribution through the rostral-caudal axis of the 
mouse striatum is uniform (Fig. 5A). PDE10A mRNA expression is decreased in the striatum 
of R6/2 mice, relative to wild-type mice, by 4 weeks of age, as determined by in situ 
hybridization (Fig. 5A; Hebb et al., 2004). PDE10A mRNA levels continue to decline until 
reaching a new steady-state level, which is approximately 25% of that found in age-matched 
wild-type, by 9 weeks of age. Expression of PDE10A begins to decline between 6 and 7 
weeks of age in R6/1 mice and continues to decline over the next 5 weeks, until reaching a 
new steady-state level of approximately 50% that of wild-type (Fig. 5B and C). Overall, three 
conclusions can be formed from in situ analysis of PDE10A expression in R6 mice. First, 
PDE10A mRNA levels do not normally change significantly within the striatum from 3 to 30 
weeks of age. This conclusion suggests there is no effect of age on the expression of PDE10A. 
Second, PDE10A mRNA levels decline, and reach a final steady-state level, in an N-mHtt-
dependent manner prior to symptom onset in both R6 lines. Third, the rate of PDE10A 
mRNA expression’s decline is dependent upon the CAG repeat length of the mutant 
huntingtin transgene, as demonstrated by the more rapid rate of PDE10A mRNA in R6/2 
mice, which express the huntingtin gene with a greater repeat length than R6/1 mice.  
www.intechopen.com
 
Alterations in Expression and Function of Phosphodiesterases in Huntington’s Disease 143 
The N-mHtt-dependent decrease in PDE10A expression in the striatum of R6 mice was 
measured using western blot. PDE10A protein levels decrease in R6/2 mice, relative to wild-
type, at 9 weeks of age and continue to decline until 15 weeks of age, when they achieve a 
new steady-state level (Fig. 5D; Hebb et al., 2004). In R6/1 mice a decrease in protein 
abundance is observed at 9 weeks of age, and the decrease continues until 18 weeks of age. 
The pattern of protein and mRNA decrease is similar in both R6 lines in that a significant 
decrease in levels is detected prior to or during motor symptom onset and the decline 
continues until a new steady state is achieved. In the case of PDE10A protein, the decrease is 
delayed, which is likely caused by a relatively long protein half-life. 
As is observed in R6 transgenic mouse models of HD, PDE10A protein expression is 
decreased in human patients suffering from HD. PDE10A protein expression was analyzed 
in post-mortem human tissue from the caudate, nucleus acumbens, and putamen of grade 3 
HD patients using western blot. When equal amounts of protein from healthy and HD 
patients were resolved by SDS-PAGE and probed with an anti-PDE10A antibody, little 
PDE10A could be detected in protein samples derived from HD patients (Fig. 6). These 
results demonstrate that PDE10A protein levels are decreased in HD, relative to age-
matched healthy individuals (Hebb et al., 2004).  
 
Fig. 5. PDE10A mRNA and protein levels decrease in the striatum of R6/1 and R6/2 HD 
transgenic mice prior to symptom onset. Panel A depicts PDE10A mRNA hybridization 
through the rostral-caudal axis of 10 week-old R6/2 HD and wild-type (WT) mice, with the 
bottom section shown in the sagittal plane. In panel B, the striatum-specific decline in 
PDE10A mRNA in R6/2 HD mice, relative to wild-type, is apparent by 7 weeks of age. 
Panel C depicts the optical density of PDE10A mRNA in situ hybridization in the lateral 
striatum of wild-type, R6/1, and R6/2 mice. In both R6/1 and R6/2 mice there is an N-
mHtt- and age-dependent decrease in PDE10A mRNA. Panel D depicts the optical density 
of PDE10A protein from a western blot membrane for protein derived from striata of wild-
type, R6/1, and R6/2 mice. Data represents means ± S.E.M. for n = 4 of each genotype and 
of mice as indicated. * P < 0.01, significant difference from age-matched wild-type. P < 0.01, 
~ significant difference from age-matched R6/1. 
The decreased steady state levels of PDE10A2 in the R6 mouse striatum are caused by an 
altered rate of transcriptional initiation, rather than an alteration in mRNA stability (Hu et 
al., 2004; Gomez et al., 2006). A comparison of the human and mouse PDE10A2 promoters 
A 
B 
C D
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reveals a high degree of conservation with respect to the presence and relative positions of 
several cis-regulatory elements. Altered expression of PDE10A2 may be a direct 
consequence of N-mHtt acting upon the transcriptional machinery present at the promoter 
of this gene (Hu et al., 2004).  
 
Fig. 6. PDE10A protein levels are lower in post-mortem samples from the caudate, nucleus 
accumbens, and putamen of patients with grade 3 HD, compared to age-matched controls. 
Lanes 1 and 2 represent 1 μg of protein derived from the caudate and nucleus accumbens of 
66 and 53 year-old non-HD males, respectively. Lanes 3 – 5 represent 1 μg of protein derived 
from the caudate, nucleus accumbens, and putamen of grade 3 HD patients of 52, 67, and 48 
year-old HD females (3 and 4) and a male (5). Lane 6 represents 1 μg of protein from the 
striatum of wild-type mice, which was included as a positive control. Lane 7 represents 1 μg 
of protein from the striatum of 12 wk-old R6/1 mice.  
3.3 Phosphodiesterase 4A mRNA levels decrease in the striatum with age 
independently of mutant huntingtin 
PDE4A expression is higher in the cortex than the striatum of wild-type and R6 mice. The 
optical density of cortical PDE4A mRNA has been measured by in situ hybridization. 
PDE4A mRNA abundance in the cortex declines as the animals age, and is significantly 
greater in wild-type mice relative to R6/2 at 3 weeks of age (Fig. 7). The decline in PDE4A 
mRNA expression is correlated with age, but not with the expression of N-mHtt, although it 
is possible that PDE4A mRNA begins to decline in R6/2 transgenic mice before it begins to 
decline in wild-type and R6/1 mice (Hebb et al., 2004). 
3.4 Conclusions 
PDE1B and 10A mRNA and protein levels are decreased in R6 mice relative to age-matched 
wild-type mice prior to motor symptom onset. PDE4A mRNA levels decline with increasing 
age. Decreased PDE1B and 10A expression in the R6 mouse models of HD is dependent 
upon expression of N-mHtt. Greater polyQ repeat length within the N-mHtt, such as in the 
fragment expressed in R6/2 mice relative to R6/1 mice, leads to earlier decreases in PDE1B 
and 10A expression. The lifespan of the R6 HD transgenic mouse models is summarized in 
figure 8. In the case of PDE10A2, decreased mRNA expression is the result of transcriptional 
interference by N-mHtt at the PDE10A2 promoter. Collectively, these data suggest 
expression of N-mHtt causes a decrease, at the level of transcription, in abundance of 
PDE1B, 10A, and possibly 4A, in the striatum (caudate/putamen). The functional 
consequence of decreased PDE expression in HD remains unclear.  
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Fig. 7. PDE4A mRNA levels decrease with age. This figure depicts the optical density of 
PDE4A mRNA in situ hybridization in the cortex of WT, R6/1, and R6/2 HD transgenic 
mice. In all genotypes, there is a decrease in striatal PDE4A mRNA expression with 
increasing age. Data represents means ± S.E.M. for n = 4 of each genotype and of mice as 
indicated. * P < 0.001, significant difference from age-matched WT. 
 
Fig. 8. Time-line of motor symptom onset, life span, and changes in PDE expression in R6/1 
and R6/2 HD transgenic mice.  
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4. Impaired function of phosphodiesterase isoforms is associated with 
various pathological conditions of the central nervous system 
HD progression is associated with distinct pathological changes in motor control and 
behaviour. Transgenic rodent models of HD that express mHtt, in part or whole, recapitulate 
many of the symptoms associated with HD and often experience cell-specific decreases in 
PDE1B and 10A mRNA expression (Table 4). However, the precise role of decreased PDE 
expression in these models is difficult to determine. Genetic knock-out of specific PDE isoforms, 
such as 1B, 4, 10A, and 11A, in mice causes phenotypic changes that often resemble the 
symptom profile of transgenic rodent models of HD (Kleppisch & Feil, 2009). Moreover, several 
mutations in specific PDE4, 6, 8, 10, and 11 isoforms are associated with disorders of the central 
nervous system, such as schizophrenia and major depressive disorder (Esposito et al., 2009). By 
comparing and contrasting the phenotype of HD to PDE knock-out models and other central 
nervous system disorders where PDE expression or activity are dysregulated, certain 
hypotheses can be made regarding the consequence of decreased PDE expression in HD.  
4.1 Genetic knock-out of specific phosphodiesterases causes distinct behavioural 
phenotypes 
Knock-out studies in which the expression of a specific PDE is eliminated by gene ablation 
or mutation reveal how changes in catalytic activity or expression of specific PDEs may 
contribute to disease pathophysiology. Mice lacking PDEs 1B, 1C, 4B, 4D, 6B, 9A, 10A, and 
11A have been generated. These mice exhibit behaviours that resemble some behaviour 
associated with schizophrenia, major depressive disorder, hyperkinesias, and HD.  
4.1.1 Phosphodiesterase 1B knock-out causes hyper-locomotion and spatial learning 
deficits in mice 
PDE1B mRNA and protein are highly expressed in the striatum relative to other brain regions 
(Table 3). Expression of PDE1B decreases prior to symptom onset in R6 mouse models of HD. 
PDE1B knock-out mice were generated using homologous recombination to remove exons 2 – 
13 of the mouse PDE1B gene (Reed et al., 2002). Knock-out of PDE1B is associated with 
increased locomotor activity, increased dopamine receptor-mediated phosphporylation of 
dopamine and cAMP-regulated neuronal phosphoprotein (DARPP-32), and performance 
deficits in spatial learning tasks. DARPP-32 is expressed in medium spiny projection neurons 
where it is phosphorylated and activated by protein kinase A following dopamine receptor-
mediated cAMP production. Upon activation, DARPP-32 inhibits protein phosphatase 1, and 
thus facilitates phosphorylation and activation of pro-survival proteins. Double knock-out 
mice lacking PDE1B and DARPP-32 do not differ in phenotype from PDE1B null mice, 
suggesting that PDE1B activity upstream of DARPP-32 represents the major modulatory 
pathway for cyclic nucleotide messenger systems in the striatum (Ehrman et al., 2006). PDE1B 
knock-out mice show increased dopamine turnover and decreased serotonin levels in the 
striatum, and model depression-like behaviours such as decreased pleasure-seeking activity 
(Siuciak et al., 2007). These data indicate enhancement of cyclic nucleotide second messenger 
systems by PDE1B knock-out causes significant changes in locomotion and dopamine-
mediated signal transduction within the striatum. Consequently, PDE1B null mice recapitulate 
the increased spontaneous locomotor activity and depression observed in HD mouse models 
and patients. Importantly during HD progression, DARPP-32 mRNA and protein levels 
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decrease in an N-mHtt dependent manner (Gomez et al., 2006). This indicates that treatments 
that alter PDE1B activity may be limited by defects in downstream DARPP-32 levels or activity. 
4.1.2 Complete phosphodiesterase 4B, or conditional phosphodiesterase 4D, knock-
out produces a schizophrenia-like phenotype in mice 
The dual-specificity PDE4 isoforms, including PDE4A, B, and D, are expressed in the 
cerebral cortex and amygdala (Siuciak et al., 2007). In HD, PDE4A mRNA declines with age 
and may contribute to changes in mood and behaviour observed during disease progression 
(Hebb et al., 2004). PDE4B knock-out mice were generated by homologous recombination of 
exons 3 - 6, which ablated the catalytic subunit of the mouse PDE4B gene (Jin et al., 1999). 
Specific knock-out of PDE4B in mice reduces prepulse inhibition, which is considered a 
mouse behavioural model of schizophrenia. The prepulse inhibition test utilizes a series of 
paired stimuli to determine whether an animal is capable of filtering external stimuli. Mice 
with normal executive function have a reduced response to the second of two, paired, 
stimuli, relative to the first. Mice exhibiting schizophrenia-like symptoms have a heightened 
response to the second stimuli due to a deficit in the ability to filter external stimuli. Mice 
lacking PDE4B are defective in their response to prepulse inhibition, and have decreased 
baseline locomotor activity (Siuciak et al., 2007). In addition, PDE4B null mice display 
anxiogenic-like behaviour, as measured by decreased head-dips in the hole board test, 
reduced transitions into the light side of a light-dark chamber, and decreased exploration of 
an open field. PDE4B null mice do not display changes in memory or nociception (Zhang et 
al., 2002). PDE4B knock-out mice display impaired reversal learning in the Morris water 
maze, but no differences in spatial memory or fear conditioning, relative to wild-type 
littermates (Rutten et al., 2009). Taken together, these data illustrate that PDE4B expression 
in the cortex and amygdala contributes to control of locomotion and anxiety-like behaviours 
and that other PDEs do not compensate for loss of PDE4B function. 
PDE4D expression is more abundant in the cerebral cortex and hippocampus than other 
brain regions. Loss of PDE4D is associated with behaviours that mimic the effects of 
antidepressants, although the precise role of PDE4D in MDD pathophysiology is unclear. 
Mice lacking PDE4D display increased mobility in the forced swim and tail-suspension 
tests, indicative of antidepressant-like behaviours in mice (Zhang et al., 2002). These data 
demonstrate PDE4 regulate susceptibility to psychoses and changes in mood. Depressive 
symptoms, such as anhedonia and decreased socializing behaviour are observed in mouse 
models of HD and may result from the decline in expression of certain PDE4 isoforms.  
4.1.3 Phosphodiesterase 10A knock-out reduces spontaneous locomotor activity and 
increases social interactions in mice 
PDE10A is highly expressed in the medium spiny projection neurons of the striatum. Protein 
and mRNA expression of PDE10A is decreased in the striatum (caudate/putamen) in human 
patients with, and mouse models of, HD. Knock-out of PDE10A in mice causes increased 
escape latency in the Morris water maze, impaired conditioned avoidance behaviour, reduced 
spontaneous locomotor activity, increased social interaction, and increased levels of striatal 
cAMP, relative to wild-type mice. PDE10A knock-out does not induce anxiety-, or depression-
like behaviours, or produce altered nociception (Siuciak et al., 2006). Further, hyper-
locomotion associated with amphetamine treatment is absent in PDE10A knock-out mice 
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(Siuciak et al., 2006). Siuciak and colleagues (2006) concluded that inhibition of PDE10A may 
represent a novel therapeutic approach to the treatment of schizophrenia. PDE10A knock-out 
mice recapitulate the reduced spontaneous locomotor activity characteristic of late-stage HD 
rigidity, and increased escape latency in the Morris water maze, but differ in that mouse 
models of HD display decreased, not increased, social interaction behaviours (Table 4).  
Species Model Behavioural phenotype Decreases in PDE 
expression
Reference 
Mouse N171-82Q • Increased spontaneous 
locomotor activity
• PDE2A (6 weeks) Schilling et al. (1999) 
  Yu et al. (2003) 
    • Progressive accelerated 
rotarod deficit 
beginning at 12 weeks
Runne et al. (2008) 
    
    
Mouse R6/1 and 
R6/2  
• Increased spontaneous 
locomotor activity 
• PDE1B (4 weeks R6/2, 
10 weeks R6/1)
Cha et al. (1998) 
 • PDE4A (with aging) Meade et al. (2002) 
  • Progressive accelerated 
rotarod deficit beginning 
at 5 and 12 weeks 
• PDE10A (4 weeks 
R6/2, 6 weeks R6/1)
Ribchester et al. 
(2004) 
  Hebb et al. (2004) 
  
  • Increased escape latency in 
the MWM  
  • Spatial learning deficit
Mouse HD cDNA • Hyperactivity (12 weeks) • PDE1B, 10A (14 weeks) Reddy et al. (1998) 
  • Decreased baseline motor 
activity (24 weeks)
Thomas et al. (2008) 
    
Mouse YAC 128 • Increased spontaneous 
locomotor activity (12 
weeks)
• PDE1B, 10A (12 weeks) Benn et al. (2007) 
 Mazarei et al. (2010) 
  • Decreased baseline motor 
activity (48 weeks)  
  • Increased escape latency in 
the MWM  
Rat huntingtin
cDNA  
• Cognitive decline (40 
weeks)
• PDE1B, PDE10A (12 
weeks)
Nguyen et al. (2008) 
  • Increased spontaneous 
locomotor activity
Cao et al. (2006) 
    
Mouse Hdh/Q72 
- 80  
• Increased aggression, 
decreased socializing 
behaviours 
• None reported Kennedy et al. (2005) 
  
  
  • Anhedonia
Mouse  Hdh/Q111 
- 150 
• Decreased baseline motor 
activity (24 weeks) 
• None reported Wheeler et al. (2002) 
    
    • Hyperactivity (4 weeks)
Table 4. Behavioural phenotypes and decreases in PDE expression observed in rodent 
models of HD. Phenotypes for specific transgenic rodent models of HD are described with 
the approximate time at which behaviours become present where possible. Changes in PDE 
expression were determined via microarray and subsequently confirmed by quantitative 
polymerase chain reaction. 
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4.1.4 Phosphodiesterase 11A knock-out produces a schizophrenia-like phenotype in 
mice 
PDE11A mRNA is expressed in the hippocampus CA1, subiculum, amygdalohippocampal 
area, and dorsal root ganglia, as demonstrated by in situ hybridization (Kelly et al., 2010). 
PDE11A knock-out mice were generated by creating a missense mutation in the catalytic 
subunit of the protein, which caused it to be non-functional. PDE11A knock-out mice exhibit 
hyperactivity in an open field test, deficits in social odour recognition and social avoidance 
behaviours, enlarged lateral ventricles, and increased CA1 activity. Overall, this knock-out 
mouse model displays symptoms that are thought to be like some symptoms seen in 
psychotic patients. 
In contrast, humans homozygous for loss-of-function mutations in PDE11A were more 
likely to suffer major depressive disorder than those with normal levels of PDE11A 
expression (Wong et al., 2006). These studies highlight the essential differences between 
mouse models and human disorders. In both cases though, deficits in social behaviours 
were present, which suggests PDE11A function is required for normal socialization 
processes. Microarray analysis of gene expression in tissue derived from rodent models of 
HD demonstrate that PDE11A expression is not changed in HD (Cha et al., 1998). The 
phenotype of PDE11A knock-out mice does, however, resemble the hyperactivity and social 
avoidance behaviours observed in rodent models of HD.  
In conclusion, altered expression of PDE1B, 4, 10A, or 11A appear to change behaviour in 
similar manners in rodent models of HD and PDE knock-out mice. The phenotypes 
associated with genetic knock-out of specific PDEs are summarized in table 5.  
Species Model 
Mutant 
gene/ gene 
locus
Associated phenotype References 
Mouse Knock-out PDE1B • Increased locomotor activity Reed et al. (2002) 
      
• Increased dopamine receptor-mediated 
phosphporylation of DARPP-32
  
      
• Spatial learning deficit
  
• Reduced pleasure-seeking activity
Mouse Knock-out PDE4B • Decreased baseline motor activity Siuciak et al. (2007) 
   
• Exaggerated locomotor response to 
amphetamine  
  
Mouse Knock-out PDE4D 
• Increased mobility in the forced swim 
and tail-suspension tests
Zhang et al. (2002) 
  
Mouse Knock-out PDE10A 
• Increased escape latency in Morris 
water maze
Siuciak et al. (2006) 
• Impaired conditioned avoidance learning
• Reduced spontaneous locomotor activity
  
Human SNPs PDE11A • Major Depressive Disorder Wong et al. (2006) 
Mouse Knock-out PDE11A • Hyperactivity Kelly et al. (2010) 
• Deficits in social avoidance behaviours
• Enlarged lateral ventricles
Table 5. CNS phenotypes related to ablation and mutations of PDE genes in mice. 
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4.2 Mutations in phosphodiesterases and their interacting proteins are associated 
with schizophrenia 
Schizophrenia is a neurological disorder described by a range of behavioural, attention, 
sensory, and executive function-based deficits (Ebix Inc. Animated Dissection of Anatomy 
for Medicine, [A.D.A.M.], 2010). Individuals with schizophrenia may experience psychoses, 
delusions, and hallucinations, collectively known as positive symptoms, as well as feelings 
of depression and social isolation, described as negative symptoms. This disorder affects 
approximately 24 million people worldwide (A.D.A.M., 2010). Schizophrenia is complex in 
that both the underlying cause and pathogenesis are highly variable when individuals 
suffering schizophrenia are compared. Several environmental factors, such as prenatal 
stress, infection, and substance abuse contribute, or predispose individuals, to developing 
schizophrenia (A.D.A.M., 2010). Genetic factors also play a role in the disorder’s etiology. 
Specific mutations in PDEs, and the proteins they interact with, are an example of these 
genetic factors. The symptom profiles of schizophrenia and HD overlap in several respects. 
First, the behavioural changes associated with both disorders are highly variable. Second, 
schizophrenia and HD are both associated with symptoms of depression and social 
withdrawal. Third, individuals with schizophrenia may exhibit hyperactivity and 
individuals with HD present with choreic movements, which may be neurologically related 
to hyperactivity (Siuciak et al., 2007). In this section the role of PDEs and their interacting 
partners in the etiology of schizophrenia will be summarized. We will demonstrate the 
important role these enzymes play in the central nervous system and how a dysregulation 
of their activity can contribute to schizophrenic disorders. 
Several authors have reported up-regulation of PDE5 protein in post-mortem tissue samples 
from patients with schizophrenia, particularly those with prominent negative symptoms 
(Akhondzadeh et al., 2011). PDE1C and PDE8B mRNA are up-regulated in post-mortem 
samples derived from the lateral cerebellum of patients with schizophrenia (Fatemi et al., 
2009). The precise cause of this up-regulation is unknown, but the data demonstrate 
schizophrenia pathogenesis is associated with dysregulation of several PDE families and 
isoforms.  
PDE10A has garnered significant attention as a potential therapeutic target for 
schizophrenia. As previously described, the PDE10A variant, PDE10A2, displays differential 
sub-cellular localization depending on local cAMP level. PDE10A2 localizes to the 
membrane and is transported along dendritic processes by palmitoylation at cysteine 11 
(Charych et al., 2010). Protein kinase A is activated by high cAMP and phosphorylates 
PDE10A2 at threonine 16, which interferes with trafficking of PDE10A2 to the membrane. 
The authors postulate that differential dopamine signalling, as observed in schizophrenia, in 
the direct and indirect striatal output pathways, would change cAMP levels and thus 
localization and activation of PDE10A2. Their model of dopamine-dependent PDE10A2 
localization and activity is summarized in figure 2.  
Mutations in the disrupted-in-schizophrenia-1 protein are considered strong genetic risk 
factors for the development of schizophrenia. Specifically, mutation of glutamine 31 to 
leucine (Q31L) or leucine 100 to proline (L100P) in the N-terminal region of this protein are 
associated with depression-like and schizophrenia-like phenotypes in mutant mice, 
respectively (Lipina et al., 2011). Disrupted-in-schizophrenia-1 protein exists in a protein 
complex with glycogen synthase kinase-3 and PDE4B in the rat dorso-lateral prefrontal 
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cortex and hippocampus. This complex localizes to the synapse in primary mouse 
hippocampal cultured neurons (Lipina et al., 2011). In protein extracts derived from the 
hippocampus or dorso-lateral prefrontal cortex of L100P mice, disrupted-in-schizophrenia-1 
protein -PDE4B binding was reduced by 75% and disrupted-in-schizophrenia-1 protein –
glycogen synthase kinase-3 binding was reduced by 50%, relative to protein extracts derived 
from mice with wild-type disrupted-in-schizophrenia-1 protein. Similarly, disrupted-in-
schizophrenia-1 protein -PDE4B binding was reduced by 50%, and disrupted-in-
schizophrenia-1 protein –glycogen synthase kinase-3 binding by 75%, in Q31L mouse 
models of depression. The group hypothesized that disrupted-in-schizophrenia-1 protein 
acts as a scaffold to integrate and down-regulate the signalling pathways of PDE4B and 
glycogen synthase kinase-3. Sub-threshold, doses of the glycogen synthase kinase-3 
inhibitor TDZD-8 and the PDE4 inhibitor rolipram effectively treat depression- and 
schizophrenia-like symptoms in both mutant mouse strains, as demonstrated by measuring 
pre-pulse inhibition deficit and mobility in the forced swim test. The authors conclude that 
disrupted-in-schizophrenia-1 protein mutations produce inappropriate interactions with 
PDE4B. The result of these inappropriate reactions was an inability to converge PDE4B and 
glycogen synthase kinase-3 signalling pathways contributing to schizophrenia-like 
phenotypes in mice. These data demonstrate the proper signalling of PDE4 isoforms is 
required for normal executive function, mood, and behaviour.  
Mutations in the PDE4B gene itself have also been examined for associations with 
schizophrenia. The existence of PDE4B gene variants was examined in a population of 169 
Caucasian patients taking antipsychotic medication. Two PDE4B variants associated with 
tardive dyskinesia and two additional variants associated with female-specific tardive 
dyskinesia were discovered (Souza et al., 2011). However, correction for multiple testing 
eliminated these variants as being truly genetically associated with the tardive dyskinesia 
observed in schizophrenia. In contrast, a similar study examined variations in the PDE4B gene 
in 837 individuals with schizophrenia and 1473 controls (Kahler et al., 2010). They found four 
variants in the PDE4B3 isoform nominally associated with schizophrenia in females, and four 
additional single nucleotide polymorphisms associated with positive symptom scores 
according to Positive And Negative Symptoms Scale (PANSS) testing of patients. Similar 
results were found in the PDE4B gene in a Japanese population, lending further support to the 
theory that certain PDE4B variants have a positive association with schizophrenia (Numata et 
al., 2009). Up-regulation of PDE4A and 4B mRNA has been observed in the frontal cortex of 
patients with schizophrenia (Fatemi et al., 2009). Overall, mutation of PDE4 isoforms, or 
changes in the level of expression of PDE4, is associated with changes in mood and behaviour 
related to schizophrenia. Therefore, decreased PDE4 expression during HD progression may 
contribute to changes in mood and behaviour as well. 
4.3 Changes in phosphodiesterase 4 mRNA expression, but not allelic variability of 
phosphodiesterases, is implicated in major depressive disorder 
Major depressive disorder is a neurological disorder characterized by emotional, attentional, 
sensory, and executive function-based deficits (A.D.A.M., 2011). Individuals with major 
depressive disorder may experience feelings of sadness, loss, anger, or frustration that 
persist for extended periods of time such that these feelings interfere with their normal 
ability to function and be productive. Major depressive disorder affects approximately 8 – 
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12% of all people at some point during their lives (A.D.A.M., 2011). Approximately 40% of 
patients suffering from HD exhibit symptoms of depression (A.D.A.M., 2011). The Hdh 
mouse models of HD exhibit anhedonia and decreased socializing behaviours, which are 
considered to be analogous to human depression (Kennedy et al., 2005). Genetic factors, or 
heritability, contribute 40 – 50% to the probability a person will suffer major depressive 
disorder (Numata et al., 2009). Changes in the mRNA expression or the activity of certain 
PDEs can contribute to major depressive disorder etiology.  
PDE4B mRNA expression, single nucleotide polymorphisms, and haplotype variants were 
examined in a large Japanese population (655) suffering major depressive disorder (Numata 
et al., 2009). No significant correlation between allelic variation and major depressive 
disorder was found. PDE4B is most likely implicated in the pathophysiology of major 
depressive disorder because of the differential mRNA expression observed in animal 
models and human patients suffering from major depressive disorder. During HD 
progression, mRNA expression of PDE4A declines in a cell-specific manner in the cortex 
(Hebb et al., 2004). Depressive symptoms often observed in individuals suffering HD, and 
mouse models of HD, may therefore be explained by a decline in PDE4 expression. 
Other authors have analyzed associations between allelic variation in PDE1A, 8A, 9A, and 
11A and major depressive disorder (Wong et al., 2006; reviewed by Esposito et al., 2009). 
Nominally significant allelic associations between these PDEs and major depressive 
disorder have been found. However, independent analyses of these data, or attempts to 
replicate these findings in other populations, have failed to demonstrate significance. Of 
these, only one demonstrated a significant association between an inactivating mutation in 
PDE11A and individuals with adrenocortical hyperplasia and major depressive disorder 
(reviewed by Esposito et al., 2009). 
4.4 Conclusions 
Transgenic mouse models of HD display locomotor and cognitive deficits, including early-
symptomatic increased spontaneous locomotor activity, late-symptomatic hypoactivity, and 
increased escape latency in the Morris water maze. These mouse models also display the 
depression-like phenotypes of anhedonia and decreased socializing behaviours (Heng et al., 
2008). Similarly, genetic ablation of PDE1B, 4, 10A, or 11A is associated with specific 
locomotor and cognitive declines. Increased locomotor activity, spatial learning deficits, and 
reduced pleasure-seeking activity are observed in PDE1B knock-out mice (Reed et al., 2002). 
Increased escape latency and reduced spontaneous locomotor activity are observed in 
PDE10A knock-out mice (Siuciak et al., 2006). These data suggest that the consequence of 
decreased PDE expression, as observed in HD, may be a change in motor control and mood.  
Human patients suffering from HD experience spontaneous choreic movements early in 
disease progression, rigidity late in disease progression, and symptoms of depression. 
Schizophrenia and major depressive disorder are two disorders of the central nervous 
system where PDE expression and/or catalytic activity are dysregulated. Therefore changes 
in PDE1B, 4, and 10A may play a contributing factor in the pathogenesis of HD and other 
central nervous system disorders. Expression and function of PDE4B and PDE11A in the 
amygdala, cortex, and hippocampus is critical to maintain normal cognitive function and 
social interaction. PDE4D also appears to be involved in social interaction and depression-
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like behaviour. Expression of PDE8B is up-regulated in the cortex and hippocampus of 
Alzheimer’s Disease patients compared to age-matched controls (Pérez-Torres et al., 2003). 
Although microarray analyses suggest no significant changes in the expression of PDE4B, 
4D, 8A, or 11A mRNA, it is interesting to note that other central nervous system disorders 
are associated with cell-specific changes in PDE expression, which may contribute to their 
pathophysiology.  
5. Pharmacological inhibition of phosphodiesterases in the central nervous 
system 
Because multiple PDE isoforms are expressed in the central nervous system (Tables 2 and 3) 
and individual isoforms are tightly coupled to specific physiological functions, 
pharmacological inhibitors may be used to treat pathological conditions of the central nervous 
system without a high likelihood of causing non-specific side effects. PDEs represent a logical 
target for competitive inhibition because concentrations of their substrate (cAMP and cGMP) 
are low (>1μM to 10 μM; Koyanagi et al., 1998). This means that competition with endogenous 
substrate could be achieved using low concentrations of PDE inhibitors. However, PDE 
isoforms share similar structure in the catalytic domain, which makes design and development 
of truly selective competitive inhibitors difficult. Within the active site of all PDE isoforms 
studied to date, 11 invariant residues have been identified which maintain a consistent 
arrangement between isoforms and are believed to be important for catalytic activity 
(Manallack et al., 2005). Nevertheless, multiple PDE competitive inhibitors have been 
developed which show some degree of isoform-specificity as demonstrated by a lower half-
maximal inhibitory concentration (IC50) for one isoform relative to other isoforms. For 
treatment of central nervous system disorders, competitive PDE inhibitors must also 
effectively cross the blood-brain-barrier. This section will review the pharmacological profile 
of PDE competitive inhibitors that show some degree of selectivity for individual PDE 
isoforms and have well known effects in the central nervous system.  
5.1 Papaverine, TP-10 and MP-10 are selective competitive inhibitors of PDE10A 
Papaverine is an opium alkaloid that was first isolated in 1848 from poppies, or Papaver 
somniferum, from which the name “papaverine” is derived (Hollman, 2005). Medical use of 
papaverine was first suggested in 1914 for treatment of hypertension and angina (Hollman, 
2005). Papaverine was shown to competitively inhibit PDE10A following quantification of 
IC50 values in mice (Siuciak et al., 2006). The IC50 of papaverine for PDE10A is 36 nM, which 
is between 9 and 52-fold lower than the IC50 for the next most easily inhibited isoform, PDE4 
(Siuciak et al., 2006).  
TP-10 and MP-10 are two PDE10A competitive inhibitors that were developed by the 
pharmaceutical company Pfizer in 2008. The IC50 of TP-10 and MP-10 for PDE10A is 
approximately 0.3 nM and 0.18 nM respectively. This is between 3,333 and 10,000-fold lower 
than the IC50 for the 18 other PDE isoforms tested (Schmidt et al., 2008), which makes these 
compounds more selective for PDE10A than papaverine. TP-10 and MP-10 are more potent 
than papaverine as 3.2 mg/kg of TP-10 administered sub-cutaneously produced a 3- and 
3.5-fold increase in extracellular cAMP and cGMP respectively in rat striatum (Schmidt et 
al., 2008). The dose of papaverine required to achieve a similar effect was 56 mg/kg (Siuciak 
et al., 2006).  
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5.2 Rolipram is a selective competitive inhibitor of PDE4 isoforms 
Rolipram is a PDE4 competitive inhibitor originally developed as an antidepressant (Kehr et 
al., 1985). The IC50 of rolipram is approximately 500 nM for PDE4 in mice (Bader et al., 2006), 
which is approximately 24-fold lower than the IC50 for PDE10A (Bader et al., 2006). Within 
the PDE4 family, rolipram seems to inhibit PDE 4A most effectively as rolipram inhibited 
immunopurified PDE4A activity in U937 human histiocytic lymphoma cells with an IC50 of 
approximately 3 nM, compared to IC50 values of approximately 130 nM and 240 nM for 
PDE4B and PDE4D respectively (Bader et al., 2006). Inhibition of PDE4B and PDE4D is 
known to contribute to the antidepressant effects of rolipram, as the ability of rolipram to 
alleviate depression-like behaviours, is partially lost in PDE4B and PDE4D knock-out mice 
(Zhang et al., 2002; Siuciak et al., 2007). 
5.3 Sildenafil is used for inhibition of PDE5A in the periphery, but also has effects in 
the central nervous system through inhibition of PDE5A and possibly PDE6 
Sildenafil (trade name Viagra) was first developed by the pharmaceutical company Pfizer 
for treatment of angina, hypertension, and erectile dysfunction (Boolell et al., 1996). The IC50 
of sildenafil for PDE5 is 3 nM as measured in human corpus cavernosum (Ballard et al., 
1998). This is between 80- and 8500-fold lower than the IC50 for PDEs 1-4 (Ballard et al., 
1998). Anti-angina, -hypertension, and –erectile dysfunction effects of sildenafil are 
mediated by inhibition of PDE5 which is enriched in smooth muscle of the lungs and corpus 
callosum (Boolell et al., 1996). PDE5 is also expressed in the brain and growing evidence 
suggests that orally delivered sildenafil has effects in the central nervous system, as 
inhibition of PDE5 in the brain is associated with improved object recognition memory in 
rats (Prickaerts et al., 2002) and altered event-related brain potentials in humans (Schultheiss 
et al., 2001). The IC50 of sildenafil for PDE6 is 9–fold greater than the IC50 for PDE5 (Ballard 
et al., 1998). Despite a higher IC50 for PDE6 than PDE5, inhibition of PDE6 in the retina is 
believed to contribute to visual disturbances reported in a minority of patients taking 
sildenafil (Marmor & Kessler, 1999). IC50 values of sildenafil for PDEs 7-11 have not yet been 
reported. Taken together, evidence suggests that sildenafil inhibits PDE5 and PDE6 in the 
central nervous system in addition to inhibiting PDE5 in the periphery.  
6. Pharmacological inhibition of phosphodiesterase activity is useful in the 
treatment of several neurological disorders 
Phosphodiesterase inhibitors are used for the treatment of embolism, thrombocytosis, 
inflammation, decreased cerebral blood flow, heart failure, asthma, chronic obstructive 
pulmonary disease, and erectile dysfunction. PDE inhibitors exhibit antidepressant, and 
nootropic (i.e. memory enhancing), properties, which has led to the development of central 
nervous system-specific PDE inhibitors for the treatment of several neurological disorders.  
6.1 Phosphodiesterase inhibitors improve cognitive and sensorimotor deficits in 
schizophrenia 
Inhibition of PDE4B, 5, and 10A, enzymes has been investigated as a potential therapeutic 
means of reducing psychoses. In particular, inhibitors of these enzymes improve attentional 
and sensorimotor deficits, as well as socializing deficits, in animal models of schizophrenia. 
www.intechopen.com
 
Alterations in Expression and Function of Phosphodiesterases in Huntington’s Disease 155 
Several research groups have investigated the clinical efficacy of PDE inhibitors for the 
treatment of both positive and negative symptoms associated with schizophrenia. Two 
common rodent models of schizophrenia have been used to examine the effect of PDEs. 
Dopamine receptor-agonist treated mice and rats exhibit stereotypy and hyperactivity, 
which are behaviours thought to model the positive symptoms of schizophrenia in rodents. 
The other pharmacological rodent model of schizophrenia is the phencyclidine-treated 
mouse or rat. Phencyclidine acts as an N-methyl-D-aspartic acid (NMDA) receptor 
antagonist. Phencyclidine-treated rodents exhibit hyperactivity, prepulse inhibition, and 
anhedonia and are considered to be rodent models of the positive and negative symptoms 
of schizophrenia. The most well-known PDE inhibitor studied for use in schizophrenia is 
rolipram. Rolipram improves cognition, memory, and prepulse inhibition deficits in 
dopamine receptor agonist-treated mice. PDE4B activity and regulation are disrupted in the 
disrupted-in-schizophrenia-1 protein-L100P transgenic mouse model of schizophrenia 
(Lipina et al., 2011). Treatment of disrupted in schizophrenia-1 protein-L100P mice with the 
PDE4-specific inhibitor rolipram (0.1 mg/kg) corrects the deficit in prepulse inhibition and 
hyperactivity without producing overt side effects. Rolipram also reduces psychoses and 
improves attentional deficits in patients with chronic schizophrenia. However, rolipram has 
been discontinued as a treatment for schizophrenia because its use is associated with 
nausea, emesis, weight loss, and acute insomnia. These adverse effects are observed 
following treatment with all known PDE4 inhibitors. Acute insomnia, as it pertains to PDE4 
inhibition, describes an inability to sleep consistently for less than 1 month during drug use 
(reviewed by Zhang et al., 2002). In addition to the adverse effects observed generally for 
PDE4 inhibitors, rolipram causes gastrointestinal pain and cardiac arrhythmia (Zhang et al., 
2002). 
PDE10A was first identified as a “druggable” target for the treatment of schizophrenia in 
1999 (Itoh et al., 2011). The PDE10A-selective inhibitor papaverine has gained attention as a 
possible treatment for schizophrenia because of its neuroprotective actions. Papaverine 
induces NGF-dependent neurite outgrowth in PC12 neuroblastoma cells (Itoh et al., 2011). 
However, another PDE10A-selective inhibitor, MP-10, has no effect on neurite outgrowth in 
this model. Therefore, the effect of papaverine on neurite outgrowth may not be mediated 
by inhibition of PDE10A. Other PDE10A-selective inhibitors, such as the imidazol[1,5-
a]pyridol[3,2-e]pyrazines, are effective at reducing stereotypy and hyperactivity in rats 
treated with phencyclidine or dopamine receptor agonists (Itoh et al, 2011). The highly 
selective PDE10A inhibitors MP-10 and TP-10 decrease hyperactivity, attenuate conditioned 
avoidance responses, recover prepulse inhibition deficits, and improve social odour 
recognition and novel object recognition in methamphetamine- or phencyclidine-treated rats 
(Kahler et al., 2010). Pfizer began a Phase I, placebo-controlled, randomized, double-blind, 
parallel assignment, safety/efficacy clinical trial for MP-10 in 2007. This trial demonstrated 
that MP-10 has a clearance of 4 mL min-1 kg-1, a half-life of 14 h, high oral bioavailability and 
low pharmacokinetic variability. Pfizer began a Phase II clinical trial for MP-10 with an 
anticipated end date of May 2008 and a primary end point of significant improvement for 
patients suffering schizophrenia on the Positive And Negative Symptoms Scale (PANSS). 
Unfortunately, this trial has been discontinued and the Pfizer website does not provide a 
clear statement regarding the reason for the trial being discontinued. Two Phase II clinical 
trials, utilizing the PDE4 inhibitor dipyridamole are ongoing at the University of Maryland 
and Hospital Espirita de Porto Alegre (United States National Institutes of Health [NIH], 
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2011). Pfizer has also disclosed a patent for PQ-10, a papaverine-like PDE10A inhibitor. 
However, this compound appears to inhibit PDE10A and the cardiac-specific PDE3A 
isoforms, and can cause hypotension (Kahler et al., 2010).  
The PDE5-selective inhibitor has been shown to improve socializing behaviours in animal 
models of schizophrenia. Sildenafil has been utilized as an adjunct therapy to risperidone 
for the treatment of patients suffering chronic schizophrenia (Akhondzedah et al., 2011). 
Forty patients were treated in a double-blind fashion with risperidone (6 mg/day), and 
sildenafil (75 mg/day) or placebo, for 8 weeks. Patients receiving sildenafil experienced a 
significant improvement compared with those given risperidone alone when symptoms 
were measured by positive and negative symptoms scale (PANSS). Importantly, no negative 
side effects were reported. The Massachusetts General Hospital recently completed a Phase 
IV clinical trial for the use of sildenafil on improving cognitive functioning, verbal memory, 
fluency, attention, spatial memory, motor speed, executive function, and reducing the 
incidence of psychoses and withdrawal symptoms in patients with schizophrenia. Their 
study utilized single daily doses of sildenafil (50 or 100 mg) for 12 days. Results have not yet 
been published (NIH, 2011). 
6.2 Phosphodiesterase inhibition improves deficits in social interaction and mood 
associated with depression 
Evidence from animal models and clinical trials demonstrating PDE inhibition could 
alleviate the negative symptoms of schizophrenia led investigators to explore the utility of 
these compounds in major depressive and bipolar disorders. Inhibition of certain PDEs can 
effectively improve depression-related symptoms in animal models. Moreover, several PDE 
inhibitors are currently being tested in clinical trials to confirm their efficacy in treating 
human depression. The animal model and clinical trial data concerning the antidepressant 
effects of PDE inhibitors add support to the utility of PDE inhibitors in treating the 
depressive symptoms observed among individuals with HD.  
Isoforms of PDE4, particularly PDE4A and D, are expressed in the hippocampus and frontal 
cortex, which are areas classically considered to be the mediators of antidepressant drug 
effects. PDE4 inhibitors, such as rolipram, were first investigated for their antidepressant 
properties in animal models 27 years ago (Zhang et al., 2002). Treatment of rodents with the 
drug reserpine is used as a model of depression. Reserpine causes hypothermia in rodents, 
which is reversed by antidepressant drugs, such as tricyclic antidepressants. Rolipram is 
capable of reversing reserpine-induced hypothermia, and reducing immobility in the forced 
swim test. More recent animal models of depression include the learned helplessness model 
and the serotonin-depletion model. These animals are more likely to engage in pleasure-
seeking activity (i.e. seek a mate) when treated with rolipram. Rolipram’s antidepressant 
activities have been confirmed by several clinical trials, yet the drug has not been marketed 
because it causes emesis and gastrointestinal complications. Despite these complications, 
rolipram effectively demonstrates the utility of PDE4 inhibition for treatment of depression. 
As an antidepressant, rolipram is 30 times more potent than the tricyclic antidepressants 
imipramine or desipramine, and the effects of rolipram are potentiated by serotonin-
selective reuptake inhibitors, suggesting serotonin-selective reuptake inhibitors and PDE 
inhibitors might be useful for the combinatorial treatment of depression (reviewed by 
Zhang et al., 2002). A new Phase II clinical trial is ongoing by the NIH to determine the 
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efficacy of low-dose rolipram for the treatment of major depressive disorder. The expected 
date of completion for this trial is December 2011. In this trial patients will receive rolipram, 
or placebo, for 3 years. During this time, symptoms of major depressive disorder will be 
monitored, brain PDE4 levels will be measured by PET scan, and the possible correlation of 
PDE4 level and major depressive disorder symptoms will be explored.  
Inhibitors of PDE5 isoforms may represent equally promising means of treating depression. 
A double-blind, placebo-controlled clinical trial examined the usefulness of sildenafil for the 
treatment of mild-to-moderate, previously untreated, depression in men suffering erectile 
dysfunction (Kennedy et al., 2005). A total of 202 men were recruited for the trial, which 
lasted 6 weeks, and volunteers were treated with 50 mg sildenafil once daily, or placebo. 
Patients treated with sildenafil had significantly improved scores for the Beck Depression 
Inventory-II (BDI-II) and the erectile dysfunction domains, which are questionnaires to 
determine the depressive state and sexual satisfaction of a patient, respectively. Similar 
results were reported in an earlier, larger clinical trial, where the Self-Esteem And 
Relationship (SEAR) questionnaire was employed (Moncada et al., 2009). Inhibitors of PDE4 
and 5 isoforms demonstrate robust antidepressant effects in animal models and clinical 
trials in men (Moncada et al., 2009). 
PDE10A inhibition has also been investigated for antidepressant properties. Hypothermia is 
not reversed in reserpine-treated mice subsequently treated with papaverine or TP-10. 
Moreover, PDE10A knock-out mice do not differ from wild-type litter mates when they are 
tested in the forced swim test, which is considered a well-established test for depression in 
rodents (Siuciak et al., 2006). 
6.3 Phosphodiesterase inhibition may be useful for cognitive enhancement in 
Alzheimer’s Disease 
Inhibitors of PDE isoforms have been investigated for their antidepressant and cognitive 
enhancement properties. Because of the ability of these compounds to enhance cognition 
and improve memory, they were tested in mouse models of Alzheimer’s Disease. Treatment 
of transgenic Alzheimer’s Disease mice (Tg2576), which over-express amyloid ǃ precursor 
protein, with the PDE5 inhibitor sildenafil improves memory function, as measured in the 
Morris water maze, and significantly increases brain-derived neurotrophic factor levels in 
the hippocampus (Cuadrado-Tejedor et al., 2011). Brain-derived neurotrophic factor 
expression is decreased in human patients suffering from Alzheimer’s Disease and major 
depressive disorder (Cuadrado-Tejedor et al., 2011). Brain-derived neurotrophic factor-
mediated signal transduction is associated with increased protein kinase A activity, 
increased levels of phosphorylated CREB, and increased CREB-dependent gene expression 
(Zuccato et al., 2010). Brain-derived neurotrophic factor mRNA and protein levels are also 
decreased in HD. Decreased brain-derived neurotrophic factor is thought to contribute to 
decreased cell survival and gross atrophy during HD progression (Zuccato et al., 2010). 
Thus, the finding that sildenafil use might increase brain-derived neurotrophic factor levels 
suggests this drug might effectively delay neurodegeneration in disorders of the central 
nervous system such as HD. 
Rolipram has also been investigated for Alzheimer’s Disease treatment because of its 
nootropic properties. Initial evidence from pre-clinical models suggested inhibition of PDE4 
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isoforms would be logical in the context of Alzheimer’s Disease because 1) they improved 
deficits in long-term memory in mouse models of Alzheimer’s Disease, 2) they improved 
neurogenesis and pre-synaptic plasticity in mouse models of neurodegeneration, and 3) they 
evoked potent anti-inflammatory responses in mice challenged with lipopolysaccharide and 
other inflammatory agents (reviewed by Esposito et al., 2009). Moreover, expression of 
PDE4B is up-regulated in hippocampal neurons and microglia of mouse models of 
Alzheimer’s Disease and autopsied Alzheimer’s Disease human tissue (Cuadrado-Tejedor et 
al., 2011). Long-term potentiation, protein kinase A activity, and CREB phosphorylation are 
improved in hippocampal slice cultures derived from Alzheimer’s Disease transgenic mice 
treated with rolipram (Cuadrado-Tejedor et al., 2011). Similarly, retention in the passive 
avoidance test is decreased, and an improvement in the Morris water maze test for memory 
is observed, in mice given amyloid ǃ protein injections to the CA1 hippocampal region and 
treated with rolipram for 32 days (Cheng et al., 2010). Furthermore, coronal sections of 
hippocampus derived from mice treated with rolipram express phosphorylated CREB at 
significantly higher levels than mice that were not given rolipram. Despite these promising 
results, rolipram per se is not a useful drug for the treatment of Alzheimer’s Disease because 
it causes emesis, insomnia, and cardiac arrhythmia. Current research in the area of PDE 
inhibitors for use in Alzheimer’s Disease is focused on developing PDE4-selective inhibitors 
that do not cause emesis. Merck conducted a Phase II clinical trial for the use of their PDE4 
inhibitor, MK-0952, on 55-year or older patients with mild-to-moderate Alzheimer’s Disease 
in 2008. The trial has been completed and no significant improvements in patient cognitive 
function or memory were reported (NIH, 2011). One Phase II clinical trial, recently 
completed by Exonhit therapeutics, is attempting to establish the usefulness of the drug 
etazolate as a therapy for the treatment of Alzheimer’s Disease. Etazolate is a PDE4 inhibitor 
and adenosine receptor antagonist. Data have not yet been published from this trial (NIH, 
2011).  
PDE1 inhibitors have shown nootropic properties in the treatment of Alzheimer’s Disease, 
where PDE1 expression does not change. PDE1 inhibitors were first utilized clinically as 
vasodilators and anti-inflammatory agents. In 2003, the PDE1 inhibitor vinpocetine was 
investigated for its actions as a nootropic for therapeutic use in Alzheimer’s Disease and 
dementia. Three clinical trials were conducted, all of which demonstrated significant 
cognitive improvement in patients treated with vinpocetine relative to those treated with 
placebo (reviewed by Szatmari & Whitehouse, 2003). However, the number of patients 
treated for a period greater than 6 months was too small for any conclusions to be drawn. 
The major side effect reported was agranulocytosis, a serious condition that reduces 
immune function. This potential adverse effect was considered too significant a risk to the 
treatment group. Consequently, no subsequent clinical investigations have been conducted.  
6.4 Phosphodiesterase inhibition improves motor function in neurodegenerative 
disorders and traumatic central nervous system injury 
PDE inhibition produces beneficial motor effects in animal models of neurodegenerative 
disorders such as Parkinson’s Disease, and multiple sclerosis, as well as spinal cord injury, 
and ischemic-stroke. PDE7 inhibition, using the selective inhibitor S14, was shown to 
improve motor function in the lipopolysaccharide model of Parkinson’s Disease, possibly 
due to protection of dopaminergic neurons in the substantia nigra (Picconi et al., 2011). 
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Long-term levodopa use by Parkinson’s Disease patients causes involuntary jerky 
movements of the arms and/or head, which is described as dyskinesia. Dyskinesia also 
occurs in mice given 6-hydroxydopamine lesions to the substantia nigra and chronically 
treated with levopdopa. Dyskinesia is reduced in these mice if they are administered striatal 
injections of zaprinast (PDE 5,6,9,11 inhibitor) or UK-343664 (PDE5 inhibitor) twice per day 
for 21 days (Picconi et al., 2011).  
 PDE5 inhibition by subcutaneous sildenafil treatment (10 mg/kg, once per day) for 8 days 
reduced the incidence and severity of abnormal movements in experimental autoimmune 
encephalomyelitis mice, a model of multiple sclerosis (Picconi et al., 2011). Sildenafil 
treatment in this study also improved neuropathology, as shown by reductions in 1) 
demyelination and axonal loss in spinal cord, 2) inflammatory cell infiltration, and 3) 
microglia activation (Picconi et al., 2011). PDE4 and PDE5 inhibition seem to play a 
beneficial role in motor recovery after traumatic injury of the central nervous system. 
Various selective PDE5 inhibitors have been shown to promote neurogenesis and improve 
motor recovery after cerebral ischemia (Picconi et al., 2011). Rolipram treatment also 
improves motor recovery following spinal cord injury in rats (Picconi et al., 2011).  
6.5 Inhibitors of phosphodiesterases 2, 3, and 5, used in the treatment of peripheral 
disorders, have deleterious effects on the central nervous system 
Several PDE inhibitors are used to treat disorders in the periphery. Although the main site 
of action for these inhibitors is peripheral tissue, several of these drugs effect central nervous 
system function either directly if they are blood-brain barrier penetrant, or indirectly via 
their effect on blood flow. The PDE2/3-selective inhibitor anagrelide is used to treat severe 
cases of essential thrombocytosis and is not considered blood-brain barrier penetrant (Sadhu 
et al., 1999). However, anagrelide is known to cause migraine headaches and dizziness. 
These effects are thought to stem from the vasodilation and decreased blood pressure often 
associated with chronic use of anagrelide.  
Perhaps the most widely known and studied peripheral PDE inhibitors with actions in the 
central nervous system are PDE5-selective inhibitors, such as sildenafil. As mentioned 
above, sildenafil – and similar drugs – are commonly used to treat clinical erectile 
dysfunction. They also demonstrate nootropic, antidepressant, and motor control-enhancing 
properties in clinical trials for, and animal models of, depression, Alzheimer’s Disease, and 
multiple scleorsis. However, sildenafil is also known to cause headaches in approximately 
10% of all users, sudden hearing loss, and anterior optic neuropathy (NIH, 2011). Sildenafil-
associated headaches are thought to be the result of altered blood flow. Sudden hearing loss 
and anterior optic neuropathy, however, are caused by PDE5 or 6 inhibition in the cochlear 
nerve and eye, respectively (NIH, 2011; see section 3.3). The Pfizer corporation recently 
completed a Phase III observational trial to determine the prevalence of anterior optic 
neuropathy in men using sildenafil for clinical erectile dysfunction. Their study found that 
the risk of developing anterior optic neuropathy for users of sildenafil was significant and 
posed a major risk to chronic users of sildenafil (odds ratio 5.73, prevalence of 0.35 per 1000 
individuals). Pfizer is currently recruiting for a Phase IV clinical trial of sildenafil to explore 
the prevalence of anterior optic neuropathy in greater detail. The Eli Lily company is 
conducting a parallel trial with another PDE5-selective inhibitor. Pfizer has also conducted 
clinical trials to determine the efficacy of sildenafil as a treatment of Miniere’s Disease. In 
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their Phase II clinical trials, Pfizer found sildenafil did not significantly improve symptoms 
associated with Meniere’s Disease, relative to placebo (NIH, 2011).  
PDE inhibition has profound effects on physiology in the central nervous system and 
periphery. Preclinical data from animal models of schizophrenia, depression, Alzheimer’s 
Disease, Parkinson’s Disease, and multiple sclerosis suggest PDE 4, 5, and 10A inhibitors 
effectively improve deficits in socializing behaviour, cognitive function, and locomotor 
activity. Clinical data from schizophrenia, depression, and Alzheimer’s Disease trials 
confirm the beneficial effects of PDE4 and 5 inhibitors on locomotor control, cognitive 
function, and mood. Unfortunately, PDE1, 4, 5, and 10A inhibitors are known to have 
certain adverse side effects, such as emesis in the case of rolipram, or anterior optic 
neuropathy in the case of sildenafil.  
Given the efficacy of PDE inhibitors at improving locomotor and cognitive deficits, 
entertaining their potential utility in HD appears logical. Schizophrenia, depression, and 
Alzheimer’s Disease share certain symptoms with HD, such as altered locomotor control, 
mood, or neurodegeneration. Therefore, the utility of PDE inhibitors has been investigated 
as a potential treatment of HD. 
7. It is uncertain whether pharmacological inhibition of phosphodiesterases 
is beneficial for treatment of Huntington’s Disease 
Because inhibition of specific PDE isoforms has been shown to effectively reduce motor, 
cognitive, and emotional changes associated with several neurological disorders such as, 
Parkinson’s Disease, schizophrenia, Alzheimer’s Disease, and major depressive disorder, 
inhibition of PDEs may improve motor, cognitive and emotional changes that occur in HD. 
Despite data that PDE10A and PDE1B mRNA and protein levels are decreased early in HD 
and PDE4A mRNA levels decrease with aging, cAMP levels have been shown to be reduced 
in striatum of pre-symptomatic STHdh Q111/111 transgenic HD mice (Gines, 2003), and 
reduced cAMP levels have been observed in cerebral spinal fluid of HD patients (Cramer et 
al., 1984), and post-mortem caudate of HD patients (Gines, 2003). It has also been reported 
that phosphorylation of CREB, a transcription factor that is phosphorylated by cAMP-
depenendent protein kinase A, is decreased in models of HD. Consequently, it has been 
theorized that the decreased PDE10A, PDE1B, and PDE4A levels present in HD progression 
may represent compensatory changes that occur in response to even earlier decreases in 
cAMP levels (Kleiman et al., 2011). By this paradigm, inhibition of PDEs early in disease 
progression may represent a valid therapeutic approach to elevate cAMP levels and 
overcome changes to gene expression, which may contribute to HD pathogenesis. It is 
unknown at this point whether loss of PDEs is compensatory or pathogenic, however 
inhibition of PDE4 and PDE10A has been tested in animal models of HD.  
7.1 PDE4 inhibition using rolipram shows beneficial effects in animal models of 
Huntington’s Disease, however adverse effects associated with PDE4 inhibitors may 
limit their usefulness in Huntington’s Disease 
The first experiments to test whether pharmacological inhibition of PDEs was beneficial in 
HD used the PDE4 inhibitor rolipram. Rolipram treatment (1.5 mg/kg, intra-peritoneal 
injection once per day) for 2 and 8 weeks in rats that had received striatal lesions by direct 
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quinolinic acid injection to the striatum, a model used to recapitulate striatal degeneration 
that occurs in HD, resulted in decreased striatal cell loss as well as increased levels of 
phosphorylated CREB in the striatum (DeMarch et al., 2007). In a follow up study, 
Demarche and colleagues (2008) tested effects of rolipram treatment in the R6/2 transgenic 
mouse model of HD. Rolipram treatment (1.5 mg/kg, intra-peritoneal injection once per 
day) beginning at 4 weeks of age and continuing until euthanasia increased survival on a 
Kaplan-Meyer curve by approximately 1.5 weeks, reduced gross brain atrophy, increased 
the number of surviving striatal neurons, reduced microglia activation, reduced the size and 
number of neuronal intranuclear inclusions, increased phosphorylated CREB levels in 
striatal and cortical neurons, and increased brain-derived neurotrophic factor levels in 
striatal cells (DeMarch et al., 2008). A later study from the same group extended previous 
findings by examining changes to the parvalbuminergic interneurons (Giampà et al., 2009). 
Parvalbuminergic interneurons display reduced CREB phosphorylation, and reductions in 
levels of a transcriptional co-activator CREB binding protein, which is believed to contribute 
to HD pathogenesis (Nucifora et al., 2001). In support of a beneficial effect of PDE4 
inhibition in this study, rolipram treatment was found to increase the number of 
parvalbumin interneurons and normalize levels of CREB binding protein, a transcriptional 
co-activator that is thought to be inhibited by N-mHtt. Rolipram treatment also increased 
motor activity in an open field test, and increased the time spent on the rotarod. Taken 
together, these studies support a beneficial effect of rolipram treatment in rat chemical-
lesion and transgenic mouse models of HD. 
Although rolipram has shown beneficial effects for treatment of HD in animal models, 
clinical use of rolipram and other PDE4 inhibitors is not being pursued due to high 
incidence of adverse effects such as emesis, gastrointestinal problems, and insomnia 
(Giampà et al., 2010). Instead HD researchers have turned to other PDEs as a therapeutic 
target. The main candidate currently being investigated is PDE10A.  
7.2 Inhibition of PDE10A produces conflicting results in mouse models of 
Huntington’s Disease 
PDE10A has been pursued as a pharmacological target for treatment of HD because 
PDE10A is selectively expressed in the caudate, which degenerates in HD (Hebb et al., 2004; 
Giampà et al., 2010; Lakics et al., 2010). To date, two studies have directly tested effects of 
PDE10A inhibitors in animal models of HD. In the first study, R6/1 and wild-type mice 
were treated with papaverine (20 mg/kg subcutaneous once daily, 30 minutes before 
behavioural testing) beginning at 8 weeks and continuing for 14 days. Wild-type mice 
displayed significantly increased anxiety-like behaviours using the light-dark test, but 
anxiety-like behaviour was absent in R6/1 mice. Reduced CREB protein levels in striatum of 
R6/1 and wild-type mice were also reported as shown by western blot and densitometric 
analysis. In the same study, effects of chronic papaverine treatment (20 mg/kg 
subcutaneous once daily for 42 days, given 30 mins before testing) in wild-type mice were 
also examined. Papaverine treatment led to distinct motor deficits, mild cognitive deficits, 
and anxiety-like behaviour as measured by rotarod, Morris Water Maze, and light-dark test 
respectively. In contrast, Giampa and colleagues (2010) showed that PDE10A inhibition 
using TP-10 (1.5 mg/kg intra-peritoneal injection, once daily) beginning at 4 weeks of age 
and continuing until euthanasia improved symptoms related to HD in R6/2 mice without 
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producing deficits in wild-type mice. TP-10 treatment was shown to improve motor deficits 
as shown by delayed development of hind paw clasping, increased time spent on rotarod, 
and increased distance travelled in an open field test. TP-10 treatment also decreased 
neurodegeneration, as shown by increased striatal and cortical neuron number, decreased 
number of neuronal intranuclear inclusions, and reduced microglia activation. Additionally, 
TP-10 treatment was shown to increase levels of phosphorylated CREB and brain-derived 
neurotrophic factor in the striatum and cortex of R6/2 mice. Differences between the results 
reported by Giampa et al. (2010) and Hebb et al. (2004) could be due to differences in 
pharmacological properties of papaverine and TP-10 or methodological differences such as 
behavioural tests used and age at which treatment was started. Consequently, effects of 
PDE10A inhibition in genetic mouse models of HD are not clear. 
Other studies provide indirect evidence that PDE10A inhibition may be beneficial for 
treatment of HD. Threlfell and colleagues (2009) report that inhibition of PDE10A using 
striatal infusion of papaverine or TP-10, or systemic administration of TP-10, increases the 
probability that medium spiny projection neurons will depolarize in response to cortical 
input as shown by single-unit extracellular recordings performed in the dorsal striatum of 
anesthetised rats. Loss of medium spiny neurons is believed to contribute to HD 
pathophysiology, so enhancement of medium spiny neurons responsiveness to cortical 
input represents a potentially beneficial effect of PDE10A inhibition in HD. Kleiman and 
colleagues (2011) observed changes in gene expression associated with chronic PDE10A 
inhibition that were predicted to provide neuroprotective effects in models of HD. 
Microarray analysis of RNA obtained from wild-type mice treated with TP-10 (25 mg/kg 
administered by oral galvage once per day for 18 days) showed down-regulation of mRNAs 
encoding histone deacetylase 4, follistatin, and claspin mRNAs in the striatum. Down-
regulation of these mRNAs has been predicted to provide neuroprotection in HD (Hughes 
et al., 1999; Freudenreich and Lahiri, 2004; Thomas et al., 2008). In this study, no differences 
in gene expression were observed in PDE10A knock-out mice treated with TP-10, thus 
indicating that the effect of TP-10 on gene expression is selective for PDE10A. Kleiman and 
colleagues (2011) also showed that CREB-mediated transcription was significantly increased 
in striatum of wild-type mice treated with TP-10 (3.2 mg/kg subcutaneously for 1 week) 
using in vivo imaging of the bioluminescence produced from a CRE driven luciferase lenti-
viral vector. Taken together, these studies provide indirect evidence that inhibition of 
PDE10A may be beneficial in HD.  
8. Conclusions 
PDE10A and 1B mRNA and protein levels are decreased early in HD (Hebb et al., 2004). 
PDE4A mRNA levels decrease with aging (Hebb et al., 2004). Impaired function of PDE 
isoforms is associated with various pathological conditions of the central nervous system, so 
decreases in PDE10A and 1B may contribute to HD pathology. However, cAMP levels are 
reduced prior to symptom onset in rodent models of HD and it has been theorized that 
decreases in PDE10A and 1B may represent compensatory changes that occur in response to 
even earlier decreases in cAMP levels (Keliman et. al., 2011). If this is true, then inhibition of 
PDEs early in disease progression represents a valid therapeutic approach to elevate cAMP 
levels and overcome changes in gene expression, which may contribute to HD pathogenesis. 
In support of this view, PDE4 inhibition via rolipram has shown beneficial results in mouse 
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models of HD (DeMarch et al., 2007; Giampa et al., 2009). Additionally, PDE10A inhibition 
by TP-10 treatment at 4 weeks of age reduces behavioural and cellular changes associated 
with HD progression in R6/2 mice (Giampa et al., 2010). Indirect evidence also supports a 
beneficial effect of PDE10A inhibition for treatment of HD, as TP-10 treatment increases the 
probability that medium spiny projection neurons fire in response to cortical input (Threfell 
et al., 2009) and both genetic ablation of PDE10A and TP-10 treatment result in gene 
expression changes that are predicted to be neuroprotective in HD (Kleiman et al., 2011). 
However, PDE10A2 mRNA expression is decreased at the level of transcription by N-mHtt 
in R6 mouse models of HD (Hu et al., 2004; Gomez et al., 2006). N-mHtt interacts with, and 
interferes with, the normal function of transcription factors and co-factors required for the 
appropriate expression of PDE10A2 (Hu et. al., 2004). These data specifically argue against 
the hypothesis that decreased PDE expression represents a compensatory mechanism on the 
part of the cell during HD progression. PDE10A inhibition by papaverine produces marked 
cognitive and motor deficits in wild-type mice, while having no beneficial effect in R6/1 
transgenic HD mice (Hebb et. al., 2004). Moreover, PDE10A knock-out mice display 
cognitive deficits, including increased escape latency in the Morris water maze, and reduced 
spontaneous locomotor activity (Siuciak et al., 2006). Ablation of PDE1B is associated with 
increased spontaneous locomotor activity and reduced pleasure-seeking behaviour. The 
phenotype of PDE10A and 1B knock-out mice resembles those observed in several 
transgenic rodent models of HD. Taken together, these data indicate that decreased 
expression of PDEs 1B, 4A, and 10A may play a pathogenic role in HD. 
HD progression is also associated with decreased expression of DARPP-32 and brain-
derived neurotrophic factor. Evidence from PDE1B knock-out mice suggests that PDE1B is 
the major up-stream regulator of DARPP-32 activity in medium spiny projection neurons 
(Reed et al., 2002). Consequently, PDE1B inhibition in the context of HD, may have limited 
efficacy as DARPP-32 levels and activity are decreased. Decreased brain-derived 
neurotrophic factor is associated with decreased cell survival in Alzheimer’s Disease and 
HD, and neuronal atrophy in major depressive disorder (Zuccato et al., 2010). Sildenafil may 
induce expression of brain-derived neurotrophic factor. However, PDE5 is not expressed at 
high levels in the caudate/putamen, so the effect of sildenafil may have little benefit in the 
treatment of HD neuronal cell loss.  
To date, the majority of data regarding changes in PDE expression, or the efficacy of PDE 
inhibition in HD, have been collected in the R6 mouse model. The R6 transgenic mouse 
model of HD is limited in several respects. R6 mice over-express an N-terminal fragment of 
mHtt (Mangiarini et al., 1996). HD progression is accelerated by N-mHtt over-expression 
and certain aspects of HD pathophysiology, such as behavioural changes, may not be 
observed (Cha et al., 1998). Other, more physiologically accurate, transgenic mouse models 
of HD recapitulate the longitudinal progression of this disorder. For example, the Hdh/Q 
model, which is a knock-in mouse model expressing exon 1 of the human huntingtin gene 
containing 72 – 150 CAG repeats within the mouse huntingtin locus (Wheeler et al., 2002), 
display locomotor symptoms resembling those observed in human patients suffering HD, as 
well as decreased socializing behaviours, and anhedonia (Kennedy et al., 2005). Future 
studies that examine longitudinal changes in cAMP levels and PDE expression in the 
striatum of HD mice may elucidate whether decreased PDE1B, 4A, and 10A expression is 
compensatory or pathogenic. If PDE reductions are shown to be compensatory in HD 
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knock-in models, clinical trials could be conducted to determine whether PDE inhibitors 
could delay HD symptom onset without producing adverse side effects. PDE1 and 4 
inhibitors cause agranulocytosis and emesis, respectively, and consequently may not be 
practical for use in treating HD. PDE10A inhibitors are not known to cause adverse side 
effects and may represent the most logical target in such clinical trials for the safe and 
effective treatment of HD. 
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